Thrombosis and Haemostasis · 1997 · 130 citations · 49 references
MedicineCardiologyPharmacologyHemostasisPreventive CardiologyTranscriptional RegulationCardiovascular DiseaseCardiovascular PathophysiologyCardiovascular PharmacologyEndothelial ActivationEndothelial Regulation Of HemostasisIschemic Heart DiseaseEndothelial-derived Tissue Factor Pathway InhibitorIschemic Heart Disease PharmacologyPlasminogen ActivatorsRenin-angiotensin System BlockadeRenin-angiotensin System InhibitorsRenin-angiotensin System ModulationRenin-angiotensin-aldosterone System InhibitionTissue Factor Activation
Angiotensin converting enzyme inhibitors (ACE-I) have been reported to prevent the recurrence of cardiovascular events. The mechanism of this decrease, however, can not be completely explained by anti-hypertensive and anti-hypertrophic effects of ACE-I. To investigate the mechanism of this decrease, we studied the regulation of plasminogen activator inhibitor-1 (PAI-1), tissue type plasminogen activator (TPA), tissue factor (TF), and tissue factor pathway inhibitor (TFPI) by angiotensin II (Ang II) in cultured rat aortic endothelial cells. Ang II increased PAI-1 and TF mRNA expression without affecting that of TPA or TFPI. These inductions were accompanied by increases in PAI-1 and TF activities and were inhibited by a type I Ang II receptor antagonist. The results suggest that Ang II decreases the antithrombotic properties of endothelial cells which increases the chance of thrombosis. Thus, inhibition of the renin-angiotensin system may be beneficial to prevent thrombus formation in treatment of ischemic heart disease.
49
J. Yun Tso, Xiao-Hong Sun, Teh‐hui Kao et al. · Nucleic Acids Research · 1985 · 1.8K citations · Full text
Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor
T J Murphy, R. Wayne Alexander, Kathy K. Griendling et al. · Nature · 1991 · 1.3K citations